Synonyms: CB-313 | Lysodren®
mitotane is an approved drug (FDA (1970), EMA (2004))
Compound class:
Synthetic organic
Comment: The molecular mechanism underlying mitotane's clinical effects is complex and poorly understood [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Used to treat inoperable adrenal cortical carcinoma (ACC), where it specifically causes the death of these cells and inhibits their production of steroid hormones. |
Mechanism Of Action and Pharmacodynamic Effects |
The precise molecular mechanism underlying mitotane's clinical effects has not been fully resolved, but may include: inhibition of steroidognesis as it is believed to inhibit two of the cytochrome P450 enzymes (CYP11A1 and CYP11B1) [2] essential for initiating steroid hormone biosynthesis and the drug may also cause apoptosis via activation of caspases 3 and 7 [1]. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |